0001209191-23-010125.txt : 20230216
0001209191-23-010125.hdr.sgml : 20230216
20230216170039
ACCESSION NUMBER: 0001209191-23-010125
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230214
FILED AS OF DATE: 20230216
DATE AS OF CHANGE: 20230216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dorval Allison
CENTRAL INDEX KEY: 0001625110
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40489
FILM NUMBER: 23639238
MAIL ADDRESS:
STREET 1: C/O INSULET CORPORATION
STREET 2: 600 TECHNOLOGY PARK DRIVE, SUITE 200
CITY: BILLERICA
STATE: MA
ZIP: 01821
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Verve Therapeutics, Inc.
CENTRAL INDEX KEY: 0001840574
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 824800132
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02215
BUSINESS PHONE: (978) 501-3026
MAIL ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02215
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-14
0
0001840574
Verve Therapeutics, Inc.
VERV
0001625110
Dorval Allison
C/O VERVE THERAPEUTICS, INC.
201 BROOKLINE AVENUE, SUITE 601
BOSTON
MA
02215
0
1
0
0
Chief Financial Officer
Stock Option (right to buy)
21.76
2023-02-14
4
A
0
182800
0.00
A
2033-02-13
Common Stock
182800
182800
D
The option was granted on February 14, 2023. 25% of the shares underlying the option will vest on February 14, 2024, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2027.
/s/ Andrew Ashe, as Attorney-in-Fact for Allison Dorval
2023-02-16